6 Strain Blend

Winclove 801

JUMP TO:
01
Summary

A randomized, placebo-controlled trial evaluated the effects of this 6-strain probiotic blend on 35 participants with IBS and visceral hypersensitivity.1 The study revealed no significant symptom improvements within the probiotic group. Interestingly, the placebo group reported improvements for various parameters such as:

  • Number of symptom-free days
  • Mean symptom composite score
  • Flatulence
  • Bloating
  • Abdominal cramps

However, it’s important to note that the study had a small sample size, which limited its ability to detect statistically significant differences between the placebo and probiotic groups.

Both groups—probiotic and placebo—showed a significant decrease in the percentage of patients with visceral hypersensitivity (76.5% and 71.4%, respectively), but the difference was not statistically significant. Additionally, pain score improvements did not significantly differ between the groups.

Key Takeaway:

Based on this study, the 6-strain probiotic blend does not appear to be superior to a placebo for managing IBS symptoms.

Recommended Dose:

None

 

References: 

  1. Ludidi S, Jonkers DM, Koning CJ, et al. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil 2014 May;26(5):705-14. [doi: 10.1111/nmo.12320]  S 
Read More…

A randomized, placebo-controlled trial evaluated the effects of this 6-strain probiotic blend on 35 participants with IBS and visceral hypersensitivity.1 The study revealed no significant symptom improvements within the probiotic group. Interestingly, the placebo group reported improvements for various parameters such as:

  • Number of symptom-free days
  • Mean symptom composite score
  • Flatulence
  • Bloating
  • Abdominal cramps

However, it’s important to note that the study had a small sample size, which limited its ability to detect statistically significant differences between the placebo and probiotic groups.

Both groups—probiotic and placebo—showed a significant decrease in the percentage of patients with visceral hypersensitivity (76.5% and 71.4%, respectively), but the difference was not statistically significant. Additionally, pain score improvements did not significantly differ between the groups.

Key Takeaway:

Based on this study, the 6-strain probiotic blend does not appear to be superior to a placebo for managing IBS symptoms.

Recommended Dose:

None

 

References: 

  1. Ludidi S, Jonkers DM, Koning CJ, et al. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil 2014 May;26(5):705-14. [doi: 10.1111/nmo.12320]  S 
Read More…
Find a probiotic with Winclove 801

There is insufficient evidence demonstrating benefits for IBS with this probiotic. Therefore, we do not provide guidance on finding a commercial product containing this strain/blend.

A randomized, placebo-controlled trial evaluated the effects of this 6-strain probiotic blend on 35 participants with IBS and visceral hypersensitivity.1 The study revealed no significant symptom improvements within the probiotic group. Interestingly, the placebo group reported improvements for various parameters such as:

  • Number of symptom-free days
  • Mean symptom composite score
  • Flatulence
  • Bloating
  • Abdominal cramps

However, it’s important to note that the study had a small sample size, which limited its ability to detect statistically significant differences between the placebo and probiotic groups.

Both groups—probiotic and placebo—showed a significant decrease in the percentage of patients with visceral hypersensitivity (76.5% and 71.4%, respectively), but the difference was not statistically significant. Additionally, pain score improvements did not significantly differ between the groups.

Key Takeaway:

Based on this study, the 6-strain probiotic blend does not appear to be superior to a placebo for managing IBS symptoms.

Recommended Dose:

None

 

References: 

  1. Ludidi S, Jonkers DM, Koning CJ, et al. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil 2014 May;26(5):705-14. [doi: 10.1111/nmo.12320]  S 
02
Results
Overall evidence quality grade
81%

This probiotic has higher quality studies in IBS populations supporting it. View our evidence evaluation framework to learn how we assess the quality of studies.

Refine by Probiotic(s) In this view, show results

Close
  • Where trash
    trash

Add condition

03
Patient Handout
Share
04
Clinical Studies
  • #
  • Study
  • Year
  • Author(s)
  • Journal
  • Reference
  • Daily Dose
  • Duration of Intervention
  • Form
  • Study Design
  • Age
  • Participants
    • Study #1

    • Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients

    • 2014
    • Ludidi S, Jonkers DM, Koning CJ, et al.

    • Neurogastroenterol Motil 2014 May;26(5):705-14

    • DOI: 10.1111/nmo.12320
    • 50 billion CFU
    • 6 weeks
    • Sachet
      • RANDOMIZED
      • DOUBLE-BLIND
      • PLACEBO-CONTROLLED

    • ADULTS

    • ITT,PP (total) n=40,35
      ITT,PP (probiotic) n=21,19
      ITT,PP (placebo) n=19,16
05
Findings from studies

#

  • Diarrhea
  • Constipation
  • Bowel Habits
  • Global IBS Symptoms
  • Abdominal Pain / Discomfort
  • Bloating / Distention
  • Gas / Flatulence
  • Nausea / Vomiting
  • Mental Health
  • Quality of Life
  • Miscellaneous Symptoms
  • Notes

  • Study #1

    • Diarrhea

      • No data

    • Constipation

      • No data

    • Bowel Habits

      • No data

    • Global IBS Symptoms

      • While individual symptoms did not improve within the probiotic group, the placebo group experienced some within-group improvements. These included an increase in the number of symptom-free days and a reduction in mean symptom composite scores, flatulence, bloating, and abdominal cramps. However, it’s important to note that the study lacked sufficient power to demonstrate statistical significance for these improvements.

      • However, it’s important to note that the study lacked sufficient power to demonstrate statistical significance for these improvements.

    • Abdominal Pain / Discomfort

      • The percentage of patients experiencing visceral hypersensitivity decreased significantly in both the probiotic and placebo groups, with reductions of 76.5% and 71.4%, respectively. However, this difference was not statistically significant between the groups.

      • Additionally, there was no notable difference in the improvement of pain scores between the probiotic and placebo groups.

    • Bloating / Distention

      • See global IBS symptom cell for further details

    • Gas / Flatulence

      • See global IBS symptom cell for further details

    • Nausea / Vomiting

      • No data

    • Mental Health

      • No data

    • Quality of Life

      • No data

    • Miscellaneous Symptoms

      • No data

    • Notes

      • No data